Arsenic trioxide capsule formulation orh 2014

Drug Overview

Arsenic trioxide capsule formulation, orh 2014, is a highly specialized, oral medicine currently being developed to fight certain types of blood cancer. Known for its powerful disease-fighting properties, this medication represents a major step forward in making cancer treatment easier and more comfortable for patients by replacing long hospital infusions with a daily pill.

Generic Name: Arsenic trioxide (oral capsule formulation)
US Brand Names: Investigational names include ORH-2014 and SY-2101. (Note: The traditional intravenous [IV] liquid form is sold under the brand name Trisenox).
Drug Class: Antineoplastic Agent / Heavy Metal Compound. Highlight: This drug is classified as a Targeted Therapy, meaning it specifically finds and attacks cancer cells without harming as many normal cells as traditional chemotherapy.
Route of Administration: Oral (taken by mouth as a capsule).
FDA Approval Status: The oral capsule formulation (ORH-2014) is currently an investigational drug in the United States and has received Orphan Drug Designation. While the IV form of arsenic trioxide is fully FDA-approved, this specific oral capsule is in advanced clinical trials (such as Phase 1 and crossover studies) to prove it is just as safe and effective as the IV version.

Read about the arsenic trioxide capsule formulation orh 2014. Our expert medical facility delivers highly specialized hematology-oncology care.

What Is It and How Does It Work? (Mechanism of Action)

Arsenic trioxide capsule formulation orh 2014 2

Arsenic trioxide is a Targeted Therapy designed to treat a specific, rare type of blood cancer called Acute Promyelocytic Leukemia (APL). Even though “arsenic” is known as a poison in large amounts, in very tiny, highly controlled medical doses, it is a life-saving medicine.

Here is how it works at the molecular level:

Targeting the Broken Protein: In APL, a genetic mistake causes two normal genes to fuse together, creating a harmful mutant protein called PML-RARα (promyelocytic leukemia/retinoic acid receptor-alpha). This mutant protein stops young blood cells from maturing, causing them to multiply out of control.
Degrading the Threat: When a patient takes ORH-2014, the arsenic trioxide binds directly to the PML part of this mutant protein. This binding acts like a tag (a process called SUMOylation), signaling the cell’s natural waste disposal system to break down and destroy the harmful PML-RARα protein.
Restoring Normal Growth and Cell Death: Once the mutant protein is destroyed, the young blood cells can finally mature into healthy white blood cells. At the same time, arsenic trioxide increases “reactive oxygen species” (ROS) inside the cancer cells. This causes damage to the cancer cell’s energy centers (mitochondria) and triggers apoptosis, which is the medical term for programmed cell death.

FDA Approved Clinical Indications

Because the ORH-2014 oral capsule is still in clinical trials, it does not yet have its own standalone FDA approvals for commercial sale in the US. However, its active ingredient—arsenic trioxide—is FDA-approved in its IV form. The oral capsule is being developed for these exact same uses:

Oncological (Cancer) Uses:
- Treatment of newly diagnosed low-risk Acute Promyelocytic Leukemia (APL), usually given together with another drug called all-trans retinoic acid (ATRA).
- Treatment of relapsed or refractory APL (cancer that has come back or did not respond to initial treatment).
- Investigational Uses for ORH-2014: Clinical trials are currently testing it for other blood disorders like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).
Non-oncological Uses:
- There are currently no FDA-approved non-cancer uses for arsenic trioxide.

Dosage and Administration Protocols

The goal of ORH-2014 is to provide the exact same amount of medicine to the body as the standard IV drip, but in a simple daily capsule.

Patient Population / Condition	Standard Dose	Frequency	Administration Time / Notes
Adults (Standard Dose)	10 mg to 15 mg	Once daily	Taken orally by mouth. Clinical trials have shown that 15 mg of the oral capsule provides the same blood levels as the standard IV dose of 0.15 mg/kg.
Administration Rules	N/A	Daily	Swallow capsules whole. Do not crush, chew, or open the capsules. Recent studies show it can be taken with or without food.
Renal (Kidney) Insufficiency	Dose Adjustment Required	Monitored	Patients with severe kidney problems may need a lower dose, as the body clears arsenic through the kidneys.
Hepatic (Liver) Insufficiency	Dose Adjustment Required	Monitored	Patients with severe liver disease must be monitored closely for toxicity, and dose reductions may be necessary.

Clinical Efficacy and Research Results

Recent clinical studies from 2020 to 2025 have shown incredibly promising results for the ORH-2014 (SY-2101) oral capsule:

Bioequivalence (Equal Strength): A major 2025 study (the ALLG APML5 trial) compared the oral capsule to the standard IV drip. The results proved they are “bioequivalent.” The amount of medicine that successfully reaches the bloodstream (measured as AUC, or area under the curve) had an oral-to-IV ratio of roughly 0.99 to 1.03. This means the pill is just as effective at delivering the drug as the IV.
Survival Rates: Because the oral drug delivers the same amount of arsenic as the IV form, it is expected to match the IV’s excellent success rates. When IV arsenic trioxide is combined with ATRA for new APL patients, the complete remission rate is nearly 100%, with a 2-year event-free survival rate of roughly 97%.
Quality of Life: The primary benefit proven in recent trials is that ORH-2014 eliminates the need for daily, hours-long IV infusions that can last for months, drastically improving the patient’s daily life and reducing hospital costs.

Safety Profile and Side Effects

Arsenic trioxide is a potent medication and requires careful medical supervision.

Black Box Warning

APL Differentiation Syndrome: A potentially life-threatening reaction where leukemia cells rapidly mature, causing lung fluid buildup, fever, and breathing problems. If this happens, doctors will immediately prescribe a steroid called dexamethasone.
Cardiac Conduction Abnormalities (QT Prolongation): The drug can change the heart’s electrical rhythm, leading to a serious irregular heartbeat.
Encephalopathy: Rarely, it can cause severe brain confusion or swelling, especially if a patient has a lack of vitamin B1.

Common Side Effects (Occur in >10% of patients)

Nausea, vomiting, and stomach pain.
Diarrhea.
Fatigue and weakness.
Headaches and skin rashes.
Elevated liver enzymes (transaminitis), showing mild liver stress.

Serious Adverse Events & Management Strategies

Heart Rhythm Issues: Patients must have their heart monitored with an ECG (electrocardiogram) regularly. Doctors will closely watch blood electrolytes (potassium and magnesium) and keep them at high-normal levels to protect the heart.
Liver Toxicity: If liver enzymes rise too high, the doctor may temporarily stop the drug until the liver recovers, then restart at a lower dose.

Connection to Stem Cell and Regenerative Medicine

Arsenic trioxide has an exciting connection to cancer stem cell research. In leukemia, there are hidden “leukemia-initiating cells”—essentially cancer stem cells that have the power to constantly renew themselves and bring the cancer back. Because ORH-2014 degrades the mutant PML-RARα protein and wakes up the body’s natural tumor-suppressing genes (like p53), it specifically strips these leukemic stem cells of their ability to self-renew. By eliminating the root stem cells of the cancer, the drug helps ensure the leukemia is completely cleared and does not regenerate, leading to long-term cures.

Patient Management and Practical Recommendations

To ensure safety and success, both doctors and patients must follow a strict care plan.

Pre-Treatment Tests

Heart Check: A baseline ECG to ensure the heart’s electrical rhythm is normal.
Blood Tests: Comprehensive metabolic panel, paying special attention to liver function, kidney function, and electrolytes (Potassium, Magnesium, and Calcium).
Genetic Testing: A bone marrow or blood test to confirm the presence of the PML-RARα mutation, ensuring the patient actually has the specific cancer this Targeted Therapy is built for.

Precautions During Treatment

Your doctor will frequently check your blood and heart rhythm.
Avoid taking any other medications, including over-the-counter drugs and herbal supplements, without telling your doctor. Many common drugs can also affect heart rhythm, which can be dangerous when combined with ORH-2014.

The “Do’s and Don’ts” List

DO take your capsule at the same time every single day to keep drug levels steady in your body.
DO drink plenty of water to stay hydrated and help your kidneys process the medicine.
DO go to the emergency room immediately if you experience a sudden fever, shortness of breath, or feel dizzy/faint.
DON’T crush, chew, or open the capsule. It must be swallowed whole.
DON’T skip a dose without speaking to your cancer care team first.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. ORH-2014 is currently an investigational drug and should only be used under the strict supervision of a qualified oncologist or hematologist within an approved clinical setting. Always consult your healthcare provider regarding any medical conditions, treatments, or questions you may have about your health or medications.